Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23920781 | 0.87 | HRH3 (0.43) | HRH3DRD3CCR2KCNH2 | |
| SCHEMBL21745492 | 0.82 | HRH3 (0.36) | HRH3 | |
| SCHEMBL4550368 | 0.80 | HRH3 (0.42) | HRH3DRD3CCR2KCNH2 | |
| SCHEMBL21157892 | 0.77 | HRH3 (0.45) | HRH3DRD3CCR2KCNH2 | |
| SCHEMBL22893242 | 0.76 | HRH3 (0.47) | HRH3DRD3CCR2KCNH2 | |
| SCHEMBL24700866 | 0.76 | HRH3 (0.47) | HRH3DRD3CCR2KCNH2 | |
| SCHEMBL26194411 | 0.75 | HRH3 (0.46) | HRH3DRD3CCR2KCNH2 | |
| SCHEMBL24256708 | 0.73 | HRH3 (0.44) | HRH3DRD3CCR2KCNH2 | |
| SCHEMBL25872792 | 0.73 | HRH3 (0.44) | HRH3DRD3CCR2KCNH2 | |
| SCHEMBL9801701 | 0.73 | HRH3 (0.46) | HRH3DRD3CCR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130769-B2 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200148705-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | PRELUDE THERAPEUTICS, INCORPORATED | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130769-B2 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein | MCL1, BCL2A1, BCL2L1 | HRH3 4814/4885DRD3 4686/4885CCR2 2115/4885 |
| US-20200148705-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | MCL1, BCL2A1, BCL2L1 | HRH3 4814/4885DRD3 4686/4885CCR2 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.